A growing body of clinical trials found that effective classic heart failure medicines (β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, etc.), developed and tested in patients with LV failure, could not improve RV dysfunction or survival in patients with RV failure (Winter et al., 2009). The gene discussed is ACE; the disease is heart failure.